hVIVO plc (formerly Open Orphan plc)
Company Profile
hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.
---two-page-company-summary-(march-2024).png "hVIVO (AIM HVO) - Two page Company summary (March 2024)")
Investor Access
Management will host a Capital Markets Event for analysts, institutional investors, and media on Wednesday 17 July 2024 at 10.00 am – 12.30 pm (BST)
Analysts, institutional investors and media are welcome to attend the in-person event. Due to restrictions on numbers, it will not be possible for all interested parties to attend in-person, however, a live webcast will be available on the Company's website for retail investors and others to view the presentations here.
To register your interest for the event or webcast, please contact Walbrook PR on +44 20 7933 8780 or email [email protected]. A recording of the presentation will be made available on the Company's website after the event.
The Company also expects to announce a trading update for the six months ended 30 June 2024 on the same day.| Event | Date |
| Year End | 31 December |
| Half Year End | 30 June |
| Preliminary Results* | April |
| Interim Results* | September |
| AGM* | May |
* Months based on previous announcements of this kind
